Edity
Immune cells as natural couriers for precision therapeutics
Rehovot, Israel · Founded 2020
- Headquarters
- Rehovot
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- edity-tx.com
- Last Round
- Series ADec 2023
- Rounds
- 2
About
Edity Therapeutics has developed a groundbreaking immune cell delivery platform that engineers therapeutic proteins and uses immune cells as natural couriers to deliver them with precision to diseased tissues anywhere in the body. The company is advancing an investigational clinical program combining CAR T therapy with AI-designed pro-inflammatory proteins to improve efficacy in solid tumors.
Summary
Edity is a Biotech company based in Rehovot, Israel, founded in 2020. Its most recent funding was a Series A round in Dec 2023. Investors include Dr. Reddy's Laboratories and OurCrowd.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...